Primary PDC—patient-derived cell culture |
-
–
a natural replacement for traditional cancer cell lines
-
–
reflection of the characteristics of the patient’s tumor
-
–
possibility of high-throughput screening
-
–
low cost
|
|
PDS—patient-derived spheroids |
|
|
PDO—patient-derived organoids |
-
–
ability to self-assemble on a scaffold that mimics the extracellular environment
-
–
ability to differentiate, forming a complex tissue structure
-
–
repetition of the structure of the primary tissue
-
–
fast distribution and suitable for high bandwidth systems
|
|
PDTSC—patient-derived tissue slice culture |
-
–
preservation of metabolic activity and morphological integrity
-
–
preservation of histopathology, tumor microenvironment, including intercellular contacts and a wide range of cells
-
–
less time spent due to fewer manipulations (model can be created within a day)
|
-
–
applicable only to solid neoplasms
-
–
do not fully reflect the complexity of the tumor, have a finite life expectancy
|
Mouse PDX—patient-derived xenografts |
-
–
reproduction of complex tumor microenvironment
-
–
tumor cell heterogeneity and original tumor architecture
-
–
immunomodulation
-
–
exposure of tumor cells to a wide range of cytokines, chemokines, growth factors and hormones in vivo
-
–
biological similarity between the human disease and the animal model
|
-
–
limited engraftment success rates, graft rejection and prolonged engraftment, requiring at least 6–7 weeks for engraftment
-
–
long time for experiments
-
–
high cost
|
Zebrafish PDX |
|
-
–
difficult translatability/applicability of dosing results;
-
–
different body temperatures between fish and humans;
-
–
short observation period;
-
–
high mortality
|
CAM-PDX |
-
–
quick establishing
-
–
easy to manipulate
-
–
high successful transplantation rate
-
–
low-cost
-
–
high-throughput
-
–
chick embryos are naturally immunodeficient;
-
–
small space requirements;
-
–
low doses of screened drugs
|
|